2) Pharmacologic inhibition of the DDR and antioxidant response through combined CHK1/2 and BCL-2 blockade could unleash endogenous replicative and oxidative stress resulting in synergistic therapeutic activity in MYC/BCL-2 positive DLBCL. Here, CHEK1 is linked to diffuse large B-cell lymphoma.